939
Views
10
CrossRef citations to date
0
Altmetric
Prostate cancer

Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up

, &
Pages 1380-1389 | Received 10 Nov 2013, Accepted 08 Apr 2014, Published online: 20 May 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Morten Høyer, Ludvig P. Muren & Bengt Glimelius. (2015) The evolution of radiotherapy techniques in the management of prostate cancer. Acta Oncologica 54:6, pages 821-824.
Read now

Articles from other publishers (8)

Amar U. Kishan, Nicholas Marco, Melanie-Birte Schulz-Jaavall, Michael L. Steinberg, Phuoc T. Tran, Jesus E. Juarez, Audrey Dang, Donatello Telesca, Wolfgang A. Lilleby & Joanne B. Weidhaas. (2022) Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Radiotherapy and Oncology 167, pages 226-232.
Crossref
Matthew G. Parry, Julie Nossiter, Thomas E. Cowling, Arunan Sujenthiran, Brendan Berry, Paul Cathcart, Noel W. Clarke, Heather Payne, Jan van der Meulen & Ajay Aggarwal. (2020) Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes. International Journal of Radiation Oncology*Biology*Physics 108:5, pages 1196-1203.
Crossref
Matthew G. Parry, Arunan Sujenthiran, Thomas E. Cowling, Julie Nossiter, Paul Cathcart, Noel W. Clarke, Heather Payne, Jan van der Meulen & Ajay Aggarwal. (2019) Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study. Journal of Clinical Oncology 37:21, pages 1828-1835.
Crossref
Jonathan Hayman, Knut H. Hole, Therese Seierstad, Jamie Perin, Theodore L. DeWeese, Phuoc T. Tran & Wolfgang Lilleby. (2019) Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. Urologic Oncology: Seminars and Original Investigations 37:4, pages 289.e19-289.e26.
Crossref
Kentaro Ishii, Toshiko Yamanaga, Ryo Ogino, Yukinari Hosokawa, Shun Kishimoto, Ryuta Nakahara, Chiaki Shimada, Ryu Kawamorita, Takuhito Tada, Yoshiki Hayashi & Toshifumi Nakajima. (2018) Bowel and urinary quality of life after whole-pelvic versus prostate-only volumetric-modulated arc therapy for localized prostate cancer. Practical Radiation Oncology 8:2, pages e49-e55.
Crossref
Barbara A Jereczek-Fossa, Delia Ciardo, Silvia Ferrario, Piero Fossati, Giuseppe Fanetti, Dario Zerini, Davide Zannoni, Cristiana Fodor, Marianna A Gerardi, Alessia Surgo, Matteo Muto, Raffaella Cambria, Ottavio De Cobelli & Roberto Orecchia. (2016) No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy. The British Journal of Radiology 89:1063, pages 20150985.
Crossref
Kentaro Ishii, Ryo Ogino, Yukinari Hosokawa, Chiaki Fujioka, Wataru Okada, Ryota Nakahara, Ryu Kawamorita, Takuhito Tada, Yoshiki Hayashi & Toshifumi Nakajima. (2016) Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer . The British Journal of Radiology 89:1062, pages 20150930.
Crossref
Wolfgang Lilleby, Amol Narrang, Gunnar Tafjord, Ljiljana Vlatkovic, Kjell Magne Russnes, Andreas Stensvold, Knut Håkon Hole, Phuoc Tran & Karsten Eilertsen. (2015) Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. Radiation Oncology 10:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.